Related Experiment Videos
Early indicators of nephrotoxicity: comparison of two antibiotics
M Cecconi1, R Manfredi, L Cecarini
1Institute of Clinical Pediatrics, University of Ancona, Italy.
Insights
Ceftazidime and netilmicin showed similar clinical efficacy in pediatric patients. Ceftazidime demonstrated superior kidney tolerance, with no observed damage to early tubular markers.
Area of Science:
- Pediatric Nephrology
- Clinical Pharmacology
- Infectious Diseases
Background:
- Antibiotic selection in pediatric infections requires balancing efficacy with potential nephrotoxicity.
- Aminoglycosides like netilmicin are effective but carry risks of kidney damage.
- Third-generation cephalosporins, such as ceftazidime, offer broad-spectrum activity and are often considered for pediatric use.
Purpose of the Study:
- To compare the clinical efficacy of ceftazidime versus netilmicin in pediatric patients.
- To evaluate the kidney tolerance of ceftazidime and netilmicin using early markers of tubular damage.
- To establish baseline values for urinary biomarkers in a healthy pediatric control group.
Main Methods:
- Randomized controlled trial involving 40 pediatric patients (6 months-10 years) allocated to ceftazidime or netilmicin.
- Administration of ceftazidime (80-100 mg/kg/day) or netilmicin (6 mg/kg/day).
- Assessment of clinical outcomes, hematological parameters, and renal function markers including beta-2-microglobulin, enzymuria, cylindruria, and urinary osmolality.
Main Results:
- Both ceftazidime and netilmicin achieved comparable clinical efficacy in treating pediatric infections.
- Ceftazidime treatment did not result in any pathological changes in early markers of tubular damage.
- Netilmicin's impact on early renal tubular damage markers was not explicitly detailed in comparison, but ceftazidime showed no adverse effects.
Conclusions:
- Ceftazidime is a clinically effective antibiotic in pediatric patients, comparable to netilmicin.
- Ceftazidime exhibits a favorable kidney tolerance profile, showing no signs of early tubular damage.
- Ceftazidime represents a potentially safer alternative to netilmicin in pediatric populations where renal function is a concern.
Abstract:
The aim of the study was the evaluation of the clinical efficacy and the kidney tolerance of ceftazidime in comparison with netilmicin in pediatric patients. Forty subjects, ranging from six months to ten years of age were randomly allocated in two groups and treated either with ceftazidime (80-100 mg/kg/day) or netilmicin (6 mg/kg/day). A control group of twenty subjects was selected in order to establish the normal values of beta 2-microglobulin and urinary enzymes excretion. beta 2-microglobulin, enzymuria, cylindruria and urinary osmolability were estimated, as well as hematological parameters. Ceftazidime was as efficacious as netilmicin in the clinical outcome and in addition it did not cause any pathological change in early markers of tubular damage.